Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 7 | 2023 | 84 | 2.700 |
Why?
|
| Tuberculosis | 8 | 2023 | 56 | 2.540 |
Why?
|
| Antitubercular Agents | 8 | 2023 | 27 | 2.360 |
Why?
|
| Aminopeptidases | 7 | 2023 | 9 | 2.150 |
Why?
|
| Pregnancy Complications, Infectious | 5 | 2022 | 99 | 1.950 |
Why?
|
| Premature Birth | 3 | 2023 | 71 | 1.850 |
Why?
|
| Health Status Disparities | 4 | 2023 | 583 | 1.690 |
Why?
|
| HIV Infections | 10 | 2022 | 2207 | 1.330 |
Why?
|
| Clioquinol | 2 | 2022 | 2 | 1.290 |
Why?
|
| Heart Arrest | 2 | 2022 | 32 | 1.060 |
Why?
|
| Mentors | 2 | 2022 | 111 | 1.010 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 4 | 0.980 |
Why?
|
| Pre-Eclampsia | 3 | 2020 | 57 | 0.910 |
Why?
|
| Ambroxol | 1 | 2022 | 1 | 0.870 |
Why?
|
| Bromhexine | 1 | 2022 | 2 | 0.870 |
Why?
|
| Antimalarials | 1 | 2022 | 48 | 0.870 |
Why?
|
| Hospital Mortality | 3 | 2020 | 183 | 0.870 |
Why?
|
| Malaria | 1 | 2022 | 68 | 0.850 |
Why?
|
| Diabetes, Gestational | 1 | 2022 | 46 | 0.850 |
Why?
|
| Pregnancy | 11 | 2023 | 1503 | 0.810 |
Why?
|
| Enzyme Inhibitors | 2 | 2020 | 396 | 0.660 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 248 | 0.590 |
Why?
|
| Humans | 27 | 2023 | 34853 | 0.580 |
Why?
|
| United States | 11 | 2023 | 3894 | 0.570 |
Why?
|
| Pregnant Women | 4 | 2023 | 48 | 0.530 |
Why?
|
| Protease Inhibitors | 2 | 2012 | 47 | 0.520 |
Why?
|
| Tandem Mass Spectrometry | 3 | 2022 | 173 | 0.520 |
Why?
|
| Drug Discovery | 2 | 2013 | 77 | 0.450 |
Why?
|
| Angiotensins | 2 | 2022 | 6 | 0.430 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 520 | 0.420 |
Why?
|
| Maternal Mortality | 2 | 2022 | 13 | 0.420 |
Why?
|
| Infant, Newborn | 3 | 2023 | 871 | 0.410 |
Why?
|
| Female | 16 | 2023 | 19873 | 0.400 |
Why?
|
| Retrospective Studies | 6 | 2022 | 1961 | 0.400 |
Why?
|
| Databases, Factual | 3 | 2020 | 288 | 0.380 |
Why?
|
| Amidohydrolases | 1 | 2009 | 10 | 0.370 |
Why?
|
| Pregnancy Complications | 3 | 2020 | 132 | 0.360 |
Why?
|
| Young Adult | 9 | 2020 | 4012 | 0.330 |
Why?
|
| Isoniazid | 2 | 2019 | 4 | 0.330 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 112 | 0.320 |
Why?
|
| Minority Groups | 2 | 2022 | 537 | 0.300 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 169 | 0.300 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2561 | 0.290 |
Why?
|
| Pregnancy Outcome | 2 | 2022 | 90 | 0.260 |
Why?
|
| HIV | 2 | 2022 | 97 | 0.260 |
Why?
|
| Chromatography, Liquid | 3 | 2022 | 140 | 0.250 |
Why?
|
| Program Evaluation | 2 | 2022 | 316 | 0.240 |
Why?
|
| Nickel | 1 | 2023 | 19 | 0.240 |
Why?
|
| Cobalt | 1 | 2023 | 23 | 0.240 |
Why?
|
| Middle Aged | 8 | 2020 | 9642 | 0.230 |
Why?
|
| Parturition | 1 | 2023 | 22 | 0.230 |
Why?
|
| Adolescent | 8 | 2020 | 5035 | 0.230 |
Why?
|
| Adult | 9 | 2020 | 11034 | 0.230 |
Why?
|
| Metals | 1 | 2023 | 95 | 0.230 |
Why?
|
| Botswana | 1 | 2022 | 5 | 0.230 |
Why?
|
| Stillbirth | 1 | 2022 | 7 | 0.230 |
Why?
|
| Chloroquine | 1 | 2022 | 19 | 0.220 |
Why?
|
| Exopeptidases | 1 | 2022 | 1 | 0.220 |
Why?
|
| Microsomes, Liver | 1 | 2022 | 69 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2012 | 203 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 984 | 0.200 |
Why?
|
| Fetal Mortality | 1 | 2020 | 3 | 0.190 |
Why?
|
| Fetal Death | 1 | 2020 | 15 | 0.190 |
Why?
|
| Appendectomy | 1 | 2020 | 16 | 0.190 |
Why?
|
| Appendicitis | 1 | 2020 | 18 | 0.190 |
Why?
|
| Oxyquinoline | 1 | 2020 | 5 | 0.190 |
Why?
|
| Curriculum | 1 | 2022 | 237 | 0.190 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2020 | 18 | 0.190 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 25 | 0.190 |
Why?
|
| Antiprotozoal Agents | 1 | 2020 | 28 | 0.180 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 51 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2020 | 42 | 0.180 |
Why?
|
| Protein Binding | 1 | 2022 | 913 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 74 | 0.170 |
Why?
|
| Chloroquinolinols | 1 | 2018 | 3 | 0.170 |
Why?
|
| Hospital Costs | 1 | 2017 | 22 | 0.160 |
Why?
|
| Comorbidity | 1 | 2020 | 606 | 0.160 |
Why?
|
| Risk Factors | 3 | 2020 | 3414 | 0.150 |
Why?
|
| Length of Stay | 1 | 2017 | 184 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 63 | 0.140 |
Why?
|
| Logistic Models | 4 | 2020 | 894 | 0.140 |
Why?
|
| Obesity | 1 | 2023 | 965 | 0.130 |
Why?
|
| Anti-HIV Agents | 2 | 2016 | 394 | 0.130 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 2333 | 0.120 |
Why?
|
| Rats | 4 | 2022 | 3261 | 0.110 |
Why?
|
| Amidines | 1 | 2012 | 3 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2019 | 517 | 0.110 |
Why?
|
| Career Choice | 2 | 2022 | 44 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2021 | 1534 | 0.100 |
Why?
|
| Child | 3 | 2022 | 2875 | 0.090 |
Why?
|
| Animals | 6 | 2022 | 14307 | 0.090 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 78 | 0.090 |
Why?
|
| Sequence Alignment | 1 | 2010 | 257 | 0.090 |
Why?
|
| Universities | 2 | 2022 | 363 | 0.090 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2010 | 145 | 0.090 |
Why?
|
| Aged | 1 | 2020 | 6448 | 0.080 |
Why?
|
| HIV-1 | 1 | 2013 | 678 | 0.080 |
Why?
|
| Students | 2 | 2022 | 452 | 0.080 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 1124 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1490 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 901 | 0.070 |
Why?
|
| Male | 6 | 2022 | 18870 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2019 | 727 | 0.070 |
Why?
|
| Prevalence | 2 | 2018 | 1425 | 0.060 |
Why?
|
| Glucuronidase | 1 | 2022 | 14 | 0.050 |
Why?
|
| Glucuronides | 1 | 2022 | 10 | 0.050 |
Why?
|
| Microsomes | 1 | 2022 | 52 | 0.050 |
Why?
|
| Leadership | 1 | 2022 | 63 | 0.050 |
Why?
|
| Capacity Building | 1 | 2022 | 78 | 0.050 |
Why?
|
| Obstetric Labor, Premature | 1 | 2020 | 12 | 0.050 |
Why?
|
| Methionine | 1 | 2020 | 28 | 0.050 |
Why?
|
| Chemistry, Physical | 1 | 2020 | 44 | 0.050 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 61 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2020 | 197 | 0.050 |
Why?
|
| Sepsis | 1 | 2020 | 76 | 0.040 |
Why?
|
| Mice | 2 | 2020 | 5668 | 0.040 |
Why?
|
| Biotransformation | 1 | 2019 | 65 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2020 | 207 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2021 | 406 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 188 | 0.040 |
Why?
|
| Abortion, Induced | 1 | 2020 | 82 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 649 | 0.040 |
Why?
|
| Drug Stability | 1 | 2018 | 110 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 178 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2020 | 467 | 0.040 |
Why?
|
| Patient Selection | 1 | 2019 | 154 | 0.040 |
Why?
|
| Linear Models | 1 | 2018 | 253 | 0.040 |
Why?
|
| Kidney | 1 | 2020 | 322 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 256 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 223 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1056 | 0.040 |
Why?
|
| Hospitals | 1 | 2017 | 86 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2018 | 231 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 570 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 358 | 0.040 |
Why?
|
| Hospitalization | 1 | 2019 | 370 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 490 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 608 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 707 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1003 | 0.030 |
Why?
|
| Depression | 1 | 2020 | 664 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 109 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 137 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2013 | 91 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2013 | 224 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 376 | 0.020 |
Why?
|